title: Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
authors.affiliation: Division of Hematology-Oncology, University of Cincinnati Medical Center, The Barrett Cancer Center, Cincinnati, OH 45267, USA. nahlehza@ucmail.uc.edu
authors.forename: Zeina A
authors.initials: ZA
authors.lastname: Nahleh
authors.forename: Abdul-Rahman
authors.initials: AR
authors.lastname: Jazieh
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives; D004967:Estrogens; D005260:Female; D000077267:Fulvestrant; D000077156:Gefitinib; D006801:Humans; D051379:Mice; D009363:Neoplasm Proteins / Q000032:analysis*; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000188:drug therapy*; D011379:Prognosis; D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology; D020239:Receptor Cross-Talk; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000037:antagonists & inhibitors; D011960:Receptors, Estrogen / Q000032:analysis* / Q000037:antagonists & inhibitors; D013629:Tamoxifen / Q000008:administration & dosage; D000068878:Trastuzumab; D014407:Tumor Cells, Cultured / Q000187:drug effects; D019139:Tumor Escape; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004958:Estradiol; D004967:Estrogens; D000077267:Fulvestrant; D000077156:Gefitinib; D009363:Neoplasm Proteins; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D013629:Tamoxifen; D000068878:Trastuzumab; C485206:pertuzumab